Clinical trial
A Study to Assess Adverse Events and Change in Disease Activity of Multiple…
NCT07059845 · AbbVie, Industry · Recruiting
Key facts
| NCT number | NCT07059845 |
|---|---|
| Title | A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer |
| Official title | A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer |
| Acronym | FLORENZA |
| Lead sponsor | AbbVie, Industry |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Mirvetuximab Soravtansine, Bevacizumab, Carboplatin |
| Enrollment | 320 |
| Start date | Nov 13, 2025 |
| Primary completion | Jan 1, 2029 |
| Completion | Jan 1, 2029 |
| First posted | Jul 11, 2025 |
| Last update posted | Dec 4, 2025 |
| Countries | Australia, South Korea |
At a glance
- 10–99 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: